Benchmarks for Screening Sensitivity & Specificity

BENCHMARKS FOR SENSITIVITY, SPECIFICITY, & FALSE NEGATIVE RATE FOR SCREENING MAMMOGRAPHY EXAMS

BASED ON BCSC DATA from 2007-2013*


Sensitivity

 

 

  Number of Screening Exams
Sensitivity** 86.9
Readers with 30+ cancers 104
True Positives† 6,367
Cancers‡ 7,323
Sensitivity(Median-50th percentile) 88
Sensitivity(25th, 75th percentiles) 84.8, 90.7
Sensitivity(10th, 90th percentiles) 80.7, 93.8
SMOOTHED PLOT OF SENSITIVITY ​​​​​​​+
 FOR 7,323 CANCERS THAT WERE IDENTIFIED AT SCREENING MAMMOGRAPHY (AMONG RADIOLOGISTS FINDING 30+ CANCERS), 2007 - 2013

Specificity

 

 

  Number of Screening Exams
Specificity§ 88.9
Readers with 1000+ non-cancers 249
True Negatives|| 1,451,753
Non-cancers# 1,633,101
Specificity (Median-50th percentile) 89.7
Specificity (25th, 75th percentiles) 85.8, 92
Specificity (10th, 90th percentiles) 82.6, 94.1
SMOOTHED PLOT OF SPECIFICITY + 
FOR 1,633,101 NON-CANCERS THAT WERE IDENTIFIED AT SCREENING (AMONG RADIOLOGISTS FINDING 1000+ NON-CANCERS), 2007 - 2013​​​​​​​

False Negative Rate

 

 

  Number of Screening Exams
False negative rate (per 1000)†† 0.7
Readers with 3000+ exams 174
False negatives‡‡ 1,156
All examinations 1,492,669
False negative rate (Median-50th percentile) 0.7
False negative rate (25th, 75th percentiles) 0.5, 1
False negative rate (10th, 90th percentiles) 0.3, 1.3
SMOOTHED PLOT OF FALSE NEGATIVE RATE +
FOR 1,492,669 SCREENING MAMMOGRAPHY EXAMS (AMONG RADIOLOGISTS WITH 3000+ EXAMS), 2007 - 2013​​​​​​​


Footnotes:
Numbers are frequencies unless otherwise indicated.
Screening Mammography Examinations: mammography examinations indicated by the radiologist to be for screening, with bilateral routine views done and no other mammogram within the last 9 months, among women without breast implants.
*  Includes examinations for radiologists with minimum numbers of cases in a given row as designated; excludes examinations for which the radiologist is unknown.
**  Sensitivity = the percentage of cancers that had an abnormal initial interpretation (BI-RADS category 0, 4, 5; Note: 3 with a recommendation for immediate follow-up was recoded as 0).
  True Positive = the number of cancers that had an abnormal initial interpretation.
‡  Cancers = the number of examinations with a tissue diagnosis of cancer within 1 year following the examination
§  Specificity = the percentage of non-cancers that had a negative initial interpretation (BI-RADS category 1, 2, or 3 with no recommendation for immediate follow-up).
||  True Negative = the number of non-cancers that had a negative initial interpretation.
#  Non-cancers = the number of examinations without a tissue diagnosis of cancer within 1 year following the examination.
††  False negative rate = the rate (per 1000 exams) of false-negative exams.
‡‡  False negatives = the number of cancers that had a negative initial interpretation.
+ For figures, An overlaid solid line indicates the 50th percentile (median), paired dashed lines indicate the 25th and 75th percentiles, and paired dotted lines indicate the 10th and 90th percentiles. A single dashed line below the median indicates the 10th and 25th percentiles are the same and a single dashed line above the median indicates the 75th and 90th percentiles are the same.
Tables and figures last updated March 23, 2017 . 

The following must be cited when reproducing this data:

"The Breast Cancer Surveillance Consortium and its data collection and sharing activities are funded by grants from the National Cancer Institute (P01CA154292, U54CA163303), Patient-Centered Outcomes Research Institute (PCS-1504-30370), and Agency for Health Research and Quality (R01 HS018366-01A1). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://www.bcsc-research.org/. More information regarding the BCSC is available at: http://bcsc-research.org/."